Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010

Keizo Yamaguchi, Yoshikazu Ishii, Kazuhiro Tateda, Chikara Shimizu, Akira Suwabe, Mitsuo Kaku, Akira Hishinuma, Shigefumi Maesaki, Yoshio Kobayashi, Shigemi Kondo, Tetsuya Matsumoto, Morihiro Iwata, Sayoko Kawakami, Yoshihito Otsuka, Masato Maekawa, Tetsuya Yagi, Yuka Yamagishi, Shinichi Fujita, Yukio Hida, Kaname NakataniSatoshi Ichiyama, Ikuko Fujimoto, Hisashi Kohno, Hakuo Takahashi, Nobuchika Kusano, Yukinori Kurokawa, Yaeko Watanabe, Kiyoshi Negayama, Hitoshi Miyamoto, Makiko Kiyosuke, Kouichi Mashiba, Katsunori Yanagihara, Yosuke Aoki, Kazufumi Hiramatsu

Research output: Contribution to journalReview article

Abstract

Surveillance of β-lactamase production and susceptibilities to antimicrobial agents including tazobactam/piperacillin(TAZ/PIPC) in 4,080 bacterial strains isolated in 2010 were conducted in Japan. β-Lactamase production was investigated over 90% of the strains of Moraxella catarrhalis, Escherichia coli, Citrobacter spp., Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, indole-positive Proteus spp., Pseudomonas aeruginosa, Acinetobacter spp. and Bacteroides fragilis group., about 60% of staphylococci and 11.1% of Haemophilus influenzae. An increase of the β-lactamase producers in H. influenzae strains was noted, when compared with previous investigations conducted between 2001 and 2006. Extended spectrum β-lactamase(ESBLs) producing strains in E. coli, K. pneumoniae and P. mirabilis were 17.8%, 3.9% and 12.8%, respectively. Increasing levels of ESBLs producers in E. coli, K. pneumoniae and P. mirabilis were investigated compared with previous investigations. Metallo β-lactamase producers in E. cloacae, P. aeruginosa and Acinetobacter spp. were 2.5%, 1.0% and 3.3%, respectively, and no strain of S. marcescens was detected. Susceptibility of 4,080 strains to TAZ/PIPC based on the criteria of the Clinical and Laboratory Standards Institute were distributed from 80.9% in P. aeruginosa to 100% in methicillin-susceptible S. aureus and coagulase-negative staphylococci, P. mirabilis, Proteus spp. (except for Proteus mirabilis) and H. influenzae including β-lactamase-negative ampicillin-resistant H. influenzae. When compared with those in previous investigations, susceptibility to TAZ/PIPC in this decade was not changed and some species of Enterobacteriaceae tend to be susceptible. From these results, TAZ/PIPC is considered as a useful initial therapeutic antimicrobial agent for the infectious diseases reported in various therapeutic guidelines.

Original languageEnglish
Pages (from-to)514-525
Number of pages12
JournalJapanese Journal of Chemotherapy
Volume61
Issue number6
Publication statusPublished - Nov 2013

Keywords

  • Susceptibility
  • Tazobactam/piperacillin
  • β-lactamase

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010'. Together they form a unique fingerprint.

  • Cite this

    Yamaguchi, K., Ishii, Y., Tateda, K., Shimizu, C., Suwabe, A., Kaku, M., Hishinuma, A., Maesaki, S., Kobayashi, Y., Kondo, S., Matsumoto, T., Iwata, M., Kawakami, S., Otsuka, Y., Maekawa, M., Yagi, T., Yamagishi, Y., Fujita, S., Hida, Y., ... Hiramatsu, K. (2013). Susceptibilities of 4,080 bacterial strains of clinical isolates to tazobactam/piperacillin and other antimicrobial agents as of 2010. Japanese Journal of Chemotherapy, 61(6), 514-525.